Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.

MLA

Tyree H. Kiser, et al. “Vasopressin, Not Octreotide, May Be Beneficial in the Treatment of Hepatorenal Syndrome: A Retrospective Study.” Nephrology Dialysis Transplantation, vol. 20, no. 9, Sept. 2005, pp. 1813–20. EBSCOhost, https://doi.org/10.1093/ndt/gfh930.

APA

Tyree H. Kiser, Douglas N. Fish, Marilee D. Obritsch, Rose Jung, Robert MacLaren, & Chirag R. Parikh. (2005). Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrology Dialysis Transplantation, 20(9), 1813–1820. https://doi.org/10.1093/ndt/gfh930

Chicago

Tyree H. Kiser, Douglas N. Fish, Marilee D. Obritsch, Rose Jung, Robert MacLaren, and Chirag R. Parikh. 2005. “Vasopressin, Not Octreotide, May Be Beneficial in the Treatment of Hepatorenal Syndrome: A Retrospective Study.” Nephrology Dialysis Transplantation 20 (9): 1813–20. doi:10.1093/ndt/gfh930.